BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19615727)

  • 1. Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer.
    Folkins AK; Saleemuddin A; Garrett LA; Garber JE; Muto MG; Tworoger SS; Crum CP
    Gynecol Oncol; 2009 Oct; 115(1):108-111. PubMed ID: 19615727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
    Folkins AK; Jarboe EA; Saleemuddin A; Lee Y; Callahan MJ; Drapkin R; Garber JE; Muto MG; Tworoger S; Crum CP
    Gynecol Oncol; 2008 May; 109(2):168-73. PubMed ID: 18342932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.
    Crum CP; Drapkin R; Kindelberger D; Medeiros F; Miron A; Lee Y
    Clin Med Res; 2007 Mar; 5(1):35-44. PubMed ID: 17456833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.
    Saleemuddin A; Folkins AK; Garrett L; Garber J; Muto MG; Crum CP; Tworoger S
    Gynecol Oncol; 2008 Nov; 111(2):226-32. PubMed ID: 18718648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
    Park KJ; Patel P; Linkov I; Jotwani A; Kauff N; Pike MC
    Histopathology; 2018 Apr; 72(5):766-776. PubMed ID: 29197096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis.
    Banet N; Kurman RJ
    Int J Gynecol Pathol; 2015 Jan; 34(1):3-8. PubMed ID: 25473746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    Patrono MG; Iniesta MD; Malpica A; Lu KH; Fernandez RO; Salvo G; Ramirez PT
    Gynecol Oncol; 2015 Dec; 139(3):568-72. PubMed ID: 26407480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
    Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
    Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
    Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
    Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
    Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.